ZA200406983B - Chimeric pancreas. - Google Patents

Chimeric pancreas. Download PDF

Info

Publication number: ZA200406983B
Authority: ZA; South Africa
Prior art keywords: tissue; composition; recipient; substance; pancreatic
Prior art date: 2002-03-25

Application number

ZA200406983A

Other languages

English (en)

Inventor

Marc R Hammerman

Original Assignee

Univ Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-25

Filing date

2004-09-01

Publication date

2005-09-22

2004-09-01 Application filed by Univ Washington filed Critical Univ Washington

2005-09-22 Publication of ZA200406983B publication Critical patent/ZA200406983B/en

Links

210000000496 pancreas Anatomy 0.000 title claims description 44
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 83
210000001519 tissue Anatomy 0.000 claims abstract description 82
238000000034 method Methods 0.000 claims abstract description 61
210000004923 pancreatic tissue Anatomy 0.000 claims abstract description 57
239000000203 mixture Substances 0.000 claims abstract description 52
229940125396 insulin Drugs 0.000 claims abstract description 48
238000002054 transplantation Methods 0.000 claims abstract description 48
102000004877 Insulin Human genes 0.000 claims abstract description 38
108090001061 Insulin Proteins 0.000 claims abstract description 38
238000011282 treatment Methods 0.000 claims abstract description 24
210000004153 islets of langerhan Anatomy 0.000 claims abstract description 20
238000003306 harvesting Methods 0.000 claims abstract description 18
210000003200 peritoneal cavity Anatomy 0.000 claims abstract description 17
230000001506 immunosuppresive effect Effects 0.000 claims abstract description 15
230000001965 increasing effect Effects 0.000 claims abstract description 13
206010062016 Immunosuppression Diseases 0.000 claims abstract description 12
206010049082 Pancreatic mass Diseases 0.000 claims abstract description 12
238000002513 implantation Methods 0.000 claims description 35
206010012601 diabetes mellitus Diseases 0.000 claims description 29
238000011161 development Methods 0.000 claims description 24
210000002747 omentum Anatomy 0.000 claims description 15
210000000612 antigen-presenting cell Anatomy 0.000 claims description 11
230000012010 growth Effects 0.000 claims description 10
239000003102 growth factor Substances 0.000 claims description 7
210000001363 mesenteric artery superior Anatomy 0.000 claims description 3
239000000126 substance Substances 0.000 claims 25
238000004519 manufacturing process Methods 0.000 claims 1
241000700159 Rattus Species 0.000 description 26
230000018109 developmental process Effects 0.000 description 23
241000699666 Mus <mouse, genus> Species 0.000 description 20
238000011694 lewis rat Methods 0.000 description 15
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
239000008103 glucose Substances 0.000 description 14
241000282898 Sus scrofa Species 0.000 description 13
210000004027 cell Anatomy 0.000 description 12
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 10
210000000056 organ Anatomy 0.000 description 10
238000010186 staining Methods 0.000 description 8
230000006870 function Effects 0.000 description 6
210000004303 peritoneum Anatomy 0.000 description 6
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
108010036949 Cyclosporine Proteins 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
239000008187 granular material Substances 0.000 description 5
210000001161 mammalian embryo Anatomy 0.000 description 5
230000035935 pregnancy Effects 0.000 description 5
229960001052 streptozocin Drugs 0.000 description 5
230000002792 vascular Effects 0.000 description 5
229930105110 Cyclosporin A Natural products 0.000 description 4
241000282412 Homo Species 0.000 description 4
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
206010052779 Transplant rejections Diseases 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
210000001198 duodenum Anatomy 0.000 description 4
230000002124 endocrine Effects 0.000 description 4
230000003248 secreting effect Effects 0.000 description 4
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
102000051325 Glucagon Human genes 0.000 description 3
108060003199 Glucagon Proteins 0.000 description 3
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 3
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
238000011316 allogeneic transplantation Methods 0.000 description 3
230000001904 diabetogenic effect Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
229960004666 glucagon Drugs 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
IDINUJSAMVOPCM-UHFFFAOYSA-N 15-Deoxyspergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 2
102400001242 Betacellulin Human genes 0.000 description 2
101800001382 Betacellulin Proteins 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
102000014413 Neuregulin Human genes 0.000 description 2
108050003475 Neuregulin Proteins 0.000 description 2
102000005157 Somatostatin Human genes 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
241000282887 Suidae Species 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
239000002981 blocking agent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
230000003345 hyperglycaemic effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
BLUYEPLOXLPVCJ-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxyethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC[C@H](O)NC(=O)CCCCCCNC(N)=N BLUYEPLOXLPVCJ-INIZCTEOSA-N 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
229960000553 somatostatin Drugs 0.000 description 2
241000894007 species Species 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
229960001967 tacrolimus Drugs 0.000 description 2
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 1
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
108010009575 CD55 Antigens Proteins 0.000 description 1
102100022002 CD59 glycoprotein Human genes 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
206010018473 Glycosuria Diseases 0.000 description 1
101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
230000004913 activation Effects 0.000 description 1
108010023082 activin A Proteins 0.000 description 1
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000781 anti-lymphocytic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229960002806 daclizumab Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000000635 electron micrograph Methods 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000003890 endocrine cell Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000004204 exocrine pancreatic function Effects 0.000 description 1
-1 exogenous insulin Chemical compound 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
210000005086 glomerual capillary Anatomy 0.000 description 1
238000007446 glucose tolerance test Methods 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
206010062198 microangiopathy Diseases 0.000 description 1
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000002988 nephrogenic effect Effects 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000000720 neurosecretory effect Effects 0.000 description 1
230000010003 pancreatic endocrine function Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
210000004258 portal system Anatomy 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010656 regulation of insulin secretion Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
210000000211 third ventricle Anatomy 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000002689 xenotransplantation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Epidemiology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA200406983A 2002-03-25 2004-09-01 Chimeric pancreas. ZA200406983B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36718102P	2002-03-25	2002-03-25

Publications (1)

Publication Number	Publication Date
ZA200406983B true ZA200406983B (en)	2005-09-22

Family

ID=28675331

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200406983A ZA200406983B (en)	2002-03-25	2004-09-01	Chimeric pancreas.

Country Status (16)

Country	Link
US (2)	US7384630B2 (fr)
EP (1)	EP1487967B1 (fr)
JP (1)	JP2005521497A (fr)
KR (1)	KR20040099350A (fr)
CN (1)	CN1643133A (fr)
AT (1)	ATE484576T1 (fr)
AU (1)	AU2003259298B2 (fr)
BR (1)	BR0308718A (fr)
CA (1)	CA2477538C (fr)
DE (1)	DE60334534D1 (fr)
EA (1)	EA200401244A1 (fr)
IL (1)	IL164250A0 (fr)
MX (1)	MXPA04009411A (fr)
NO (1)	NO20044540L (fr)
WO (1)	WO2003083064A2 (fr)
ZA (1)	ZA200406983B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL165425A0 (en) *	2004-11-28	2006-01-15	Yeda Res & Dev	Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US20090155229A1 (en) *	2004-12-06	2009-06-18	Avner Yayon	Chondrocyte-based implant for the delivery of therapeutic agents
WO2007023491A2 (fr) *	2005-08-24	2007-03-01	Yeda Research And Development Co. Ltd.	Cellules tolerogeniques derivees de donneurs universels et destinees a induire une tolerance a la transplantation non syngenique
EP1926459B1 (fr)	2005-09-19	2015-01-07	Histogenics Corporation	Matrice support de cellules dont la densite des pores et la porosite sont definies specifiquement de maniere uniforme verticalement et organisees de maniere non aleatoire, et procede de preparation de celle-ci
US8685107B2 (en)	2007-07-03	2014-04-01	Histogenics Corporation	Double-structured tissue implant and a method for preparation and use thereof
US20090054984A1 (en)	2007-08-20	2009-02-26	Histogenics Corporation	Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8709400B2 (en) *	2009-07-27	2014-04-29	Washington University	Inducement of organogenetic tolerance for pancreatic xenotransplant
CN102858380B (zh) *	2009-08-02	2016-03-23	学校法人东京女子医科大学	胰岛细胞片、制造方法及其利用方法
US9420770B2 (en)	2009-12-01	2016-08-23	Indiana University Research & Technology Corporation	Methods of modulating thrombocytopenia and modified transgenic pigs
US10077420B2 (en)	2014-12-02	2018-09-18	Histogenics Corporation	Cell and tissue culture container

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5804178A (en) *	1986-11-20	1998-09-08	Massachusetts Institute Of Technology	Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
EP0552336A1 (fr) *	1991-08-02	1993-07-28	Systemix, Inc.	Implants primordiaux dans des hotes immunodeficients
EP0642784B1 (fr) *	1993-09-07	1999-05-19	Gerhard Dr. Gergely	Mélange effervescent contenant des sels alcalins ou lysinates de principes actifs acides insolubles ou à faible solubilité
US5560911A (en) *	1993-10-12	1996-10-01	Oklahoma Medical Research Foundation	Method of inhibiting acute complement mediated cytotoxicity with anti-idiotypic antibodies
US5629194A (en) *	1994-10-21	1997-05-13	Diacrin, Inc.	Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
EP1257282A4 (fr)	1999-12-06	2003-05-02	Gen Hospital Corp	Cellules souches pancreatiques et leur utilisation en transplantation
AU2001274860A1 (en) *	2000-05-18	2001-11-26	Biotransplant, Inc.	Process for reducing antibody response against xenografts
US20030031652A1 (en) *	2001-04-16	2003-02-13	Bernhard Hering	Systems and methods for inducing mixed chimerism

2003
- 2003-03-24 DE DE60334534T patent/DE60334534D1/de not_active Expired - Lifetime
- 2003-03-24 WO PCT/US2003/009091 patent/WO2003083064A2/fr active Application Filing
- 2003-03-24 AU AU2003259298A patent/AU2003259298B2/en not_active Ceased
- 2003-03-24 US US10/395,552 patent/US7384630B2/en not_active Expired - Fee Related
- 2003-03-24 AT AT03745590T patent/ATE484576T1/de not_active IP Right Cessation
- 2003-03-24 IL IL16425003A patent/IL164250A0/xx unknown
- 2003-03-24 EP EP03745590A patent/EP1487967B1/fr not_active Expired - Lifetime
- 2003-03-24 MX MXPA04009411A patent/MXPA04009411A/es unknown
- 2003-03-24 JP JP2003580500A patent/JP2005521497A/ja not_active Withdrawn
- 2003-03-24 KR KR10-2004-7014872A patent/KR20040099350A/ko not_active Application Discontinuation
- 2003-03-24 CN CNA038066998A patent/CN1643133A/zh active Pending
- 2003-03-24 BR BR0308718-2A patent/BR0308718A/pt not_active IP Right Cessation
- 2003-03-24 EA EA200401244A patent/EA200401244A1/ru unknown
- 2003-03-24 CA CA002477538A patent/CA2477538C/fr not_active Expired - Fee Related
2004
- 2004-09-01 ZA ZA200406983A patent/ZA200406983B/en unknown
- 2004-10-22 NO NO20044540A patent/NO20044540L/no not_active Application Discontinuation
2008
- 2008-05-09 US US12/118,430 patent/US20080318202A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030198628A1 (en)	2003-10-23
CN1643133A (zh)	2005-07-20
US20080318202A1 (en)	2008-12-25
KR20040099350A (ko)	2004-11-26
CA2477538C (fr)	2008-01-29
WO2003083064A2 (fr)	2003-10-09
DE60334534D1 (de)	2010-11-25
US7384630B2 (en)	2008-06-10
BR0308718A (pt)	2005-01-04
WO2003083064A3 (fr)	2004-03-25
MXPA04009411A (es)	2005-01-25
EP1487967A2 (fr)	2004-12-22
EP1487967B1 (fr)	2010-10-13
CA2477538A1 (fr)	2003-10-09
IL164250A0 (en)	2005-12-18
EP1487967A4 (fr)	2005-05-11
AU2003259298A1 (en)	2003-10-13
ATE484576T1 (de)	2010-10-15
EA200401244A1 (ru)	2005-02-24
NO20044540L (no)	2004-10-22
JP2005521497A (ja)	2005-07-21
AU2003259298B2 (en)	2006-08-31

Publication	Publication Date	Title
US20080318202A1 (en)	2008-12-25	Chimeric pancreas
Korbutt et al.	1996	Large scale isolation, growth, and function of porcine neonatal islet cells.
JP2005533746A (ja)	2005-11-10	ランゲルハンス島の幹細胞および真性糖尿病の処置におけるその使用
JP2002502823A (ja)	2002-01-29	移植における補刺激遮断および混合キメラ現象
JP2003523323A (ja)	2003-08-05	膵臓幹細胞および移植におけるその使用
Ramesh et al.	2013	Pancreatic islet transplantation in type 1 diabetes mellitus: an update on recent developments
LACY et al.	1989	Effect of transplantation site and αL3T4 treatment on survival of rat, hamster, and rabbit islet xenografts in mice
US20040082064A1 (en)	2004-04-29	Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
EP2216033B1 (fr)	2013-11-06	Méthode de traitement d'une maladie par transplantation d'organes ou de tissus allogenes or xenogenes
US20090162331A1 (en)	2009-06-25	Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
Hammerman	2002	Transplantation of embryonic kidneys
Emerich	2002	Islet transplantation for diabetes: current status and future prospects
Veld et al.	2006	Xenotransplantation of purified pre‐natal porcine beta cells in mice normalizes diabetes when a short anti‐CD4–CD8 antibody treatment is combined with transient insulin injections
AU2011224113B2 (en)	2013-10-03	Compositions containing Sertoli cells and myoid cells and use thereof in cellular transplants
Reisner	2007	Growing organs for transplantation from embryonic precursor tissues
Sands	2005	Thymic epithelial cell transplantation to the host thymus: Studies in immunomodulation and tolerance induction
JPH09500364A (ja)	1997-01-14	異種移植片の胸腺
Wang	1999	Approaches to induce islet allograft tolerance by liver allografting and to improve fetal pig islet function by gut hormones
ZA200507056B (en)	2006-05-31	Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues